RNAZ Analyst Ratings

TransCode Therapeutics, Inc. (RNAZ) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $4.8M, listed on NASDAQ, employing roughly 7 people, carrying a beta of 1.40 to the broader market. TransCode Therapeutics, Inc. Led by Philippe Calais, public since 2021-07-08.

Consensus: Mixed from 0 analysts.

Recent Upgrades & Downgrades

How to Read RNAZ Analyst Coverage

Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.

For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.

Learn how analyst ratings is reported and how to read the data →

Frequently asked RNAZ analyst ratings questions

What is the RNAZ consensus price target?

Consensus price target is not currently available for RNAZ.

What is the analyst rating consensus on RNAZ?

Analyst rating consensus is not currently available for RNAZ.

What recent ratings actions has RNAZ seen?

The five most recent ratings actions on RNAZ appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.

How do analyst targets affect RNAZ options pricing?

Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.